Evidence map›Paper›PMID 41090868›Full record

ArticleNanomaterials (Basel, Switzerland)2025

Efficacy of Nanofiber Sheets Incorporating Oxaliplatin in Gastrointestinal Cancer Xenograft Models.

Fusao Sumiyama, Hoang Hai Duong, Hideyuki Matsushima, Kosuke Matsui, Terufumi Yoshida, Hidekazu Yamamoto, Hisashi Kosaka, Mitsugu Sekimoto, Van Khanh Nguyen, Thanh Tung Lai and 7 more

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Fusao SumiyamaDepartment of Hepatobiliary Surgery, Kansai Medical University, Osaka 573-1191, Japan.
Hoang Hai DuongDepartment of Hepatobiliary Surgery, Kansai Medical University, Osaka 573-1191, Japan.
Hideyuki MatsushimaDepartment of Hepatobiliary Surgery, Kansai Medical University, Osaka 573-1191, Japan.
Kosuke MatsuiDepartment of Hepatobiliary Surgery, Kansai Medical University, Osaka 573-1191, Japan.ORCID 0000-0002-7274-0177
Terufumi YoshidaDepartment of Colorectal Surgery, Kansai Medical University, Osaka 573-1191, Japan.ORCID 0000-0002-9235-1830
Hidekazu YamamotoDepartment of Hepatobiliary Surgery, Kansai Medical University, Osaka 573-1191, Japan.ORCID 0000-0003-4734-5084
Hisashi KosakaDepartment of Hepatobiliary Surgery, Kansai Medical University, Osaka 573-1191, Japan.ORCID 0000-0002-2926-9973
Mitsugu SekimotoDepartment of Surgery, Kansai Medical University, Osaka 573-1191, Japan.
Van Khanh NguyenDepartment of Hepatobiliary Surgery, Kansai Medical University, Osaka 573-1191, Japan.
Thanh Tung LaiDepartment of Hepatobiliary Surgery, Kansai Medical University, Osaka 573-1191, Japan.ORCID 0000-0002-4230-9781
Takuya OhigashiDepartment of Hepatobiliary Surgery, Kansai Medical University, Osaka 573-1191, Japan.
Tomoya O AkamaDepartment of Pharmacology, Kansai Medical University, Osaka 573-1191, Japan.ORCID 0000-0003-4248-6929
Kengo YoshiiDepartment of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto 602-0841, Japan.
Emiho OeResearch Center for Macromolecules and Biomaterials, National Institute for Materials Science (NIMS), Ibaraki 305-0047, Japan.ORCID 0000-0001-7326-7740
Nanami FujisawaResearch Center for Macromolecules and Biomaterials, National Institute for Materials Science (NIMS), Ibaraki 305-0047, Japan.
Mitsuhiro EbaraResearch Center for Macromolecules and Biomaterials, National Institute for Materials Science (NIMS), Ibaraki 305-0047, Japan.ORCID 0000-0002-7906-0350
Masaki KaiboriDepartment of Hepatobiliary Surgery, Kansai Medical University, Osaka 573-1191, Japan.ORCID 0000-0002-0577-3921

Funding

Grant-in-Aid for Transformative Research Areas (A) 20H05877Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Scientific Research (C) 21K08762Kansai Medical University research grant (D2)
6 · The paper itself

Abstract

Oxaliplatin is an anticancer drug used to treat colorectal and gastric cancers. In many cases, chemotherapy is discontinued due to adverse events caused by anticancer drugs. To address this challenge, we developed a sustained-release drug delivery system using polycaprolactone sheets embedded with oxaliplatin (oxaliplatin sheets) and evaluated their therapeutic potential in murine models of colon and gastric cancers. Antitumor efficacy was compared with conventional intraperitoneal administration by monitoring tumor volume, body weight, and systemic oxaliplatin concentrations over 21 days, along with histopathological assessment of tumors and hepatic tissue. Oxaliplatin sheets demonstrated superior tumor suppression, significantly reduced Ki-67 positivity, and mitotic indices. Additionally, antitumor effects and blood oxaliplatin levels were consistent regardless of implantation site. Notably, oxaliplatin sheets significantly decreased weight loss compared with intraperitoneal administration. In our analysis of liver pathology, we found that hepatic sinusoidal obstruction and hepatocellular degeneration were significantly increased after intraperitoneal administration compared with untreated mice and mice treated with oxaliplatin sheets. Furthermore, treatment with oxaliplatin sheets improved survival. Thus, our oxaliplatin sheets exhibited effective tumor control and reduced side effects, indicating their potential as a promising treatment for advanced gastric and colorectal cancers.

Indexed as

COLO 205electrospun nanofiber sheetMKN 45oxaliplatinpolycaprolactone

Identifiers

PMID41090868
PMCPMC12526398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.